Researchers wearing headlamps and protective suits race to untangle the claws and wings of bats caught up in a big net after dark in the Philippine province of Laguna.
The tiny animals are carefully placed in cloth bags to be taken away, measured and swabbed, with details logged, and saliva and fecal matter collected for analysis before they are returned to the wild.
The researchers call themselves the “virus hunters,” tasked with catching thousands of bats to develop a simulation model they hope will help the world avoid a pandemic similar to COVID-19, which has killed more than 2.7 million people.
The Japanese-funded model is to be developed over the next three years by the University of the Philippines Los Banos, which hopes the bats will help in predicting the dynamics of a coronavirus outbreak by analyzing factors such as climate, temperature and ease of spread, including to humans.
“What we’re trying to look into are other strains of coronavirus that have the potential to jump to humans,” said ecologist Phillip Alviola, the leader of the group, who has studied bat viruses for more than a decade. “If we know the virus itself and we know where it came from, we know how to isolate that virus geographically.”
Beyond work in the laboratory, the research requires lengthy field trips, involving traipsing for hours through thick rainforest, and precarious night hikes on mountains covered in rocks, tree roots, mud and moss.
The group also targets bat roosts in buildings, setting up mist nets before dusk to catch bats and extract samples by the light of torches.
Each bat is held steady by the head as researchers insert tiny swabs into their mouths and record wingspans with plastic rulers, to try and see which of the more than 1,300 species and 20 families of bats are most susceptible to infections.
Researchers wear protective suits, masks and gloves when in contact with the bats, as a precaution against catching viruses.
“It’s really scary these days,” said Edison Cosico, who is assisting Alviola. “You never know if the bat is already a carrier. What we’re after is finding out if there are any more viruses from bats that can be transmitted to humans. We’ll never know if the next one is just like COVID.”
Host species, such as bats, usually display no symptoms of the pathogens, although they can be devastating if transmitted to humans or other animals.
Deadly viruses to have originated from bats include Ebola, SARS and Middle East respiratory syndrome.
Humans’ exposure and closer interaction with wildlife means the risk of disease transmission is now higher than ever, bat ecologist Kirk Taray said.
“By having baseline data on the nature and occurrence of the potentially zoonotic virus in bats, we can somehow predict possible outbreaks,” Taray said.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very